Review anchor
Melanocyte-stimulating hormone receptor
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
Evidence Snapshot
Melanocyte-stimulating hormone receptor
CHEMBL4077
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Melanocyte-stimulating hormone receptor as ChEMBL target CHEMBL4077, mapped to UniProt Q01727. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4077
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q01727
Melanocyte-stimulating hormone receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Melanocyte-stimulating hormone receptor matters
Melanocyte-stimulating hormone receptor is reviewed as Melanocyte-stimulating hormone receptor (UniProt Q01727); the current evidence base includes 2 approved drugs, 882 compounds, and 97 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Melanocyte-stimulating hormone receptor
Melanocyte-stimulating hormone receptor Sequence length is 315 aa.
Review this target as Melanocyte-stimulating hormone receptor, mapped to UniProt Q01727. Sequence length is 315 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q01727
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 882 compounds, and 97 assays for this target. The dominant activity type is EC50. CHEMBL441738 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL441738 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Melanocyte-stimulating hormone receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q01727, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
882
Total Compounds
97
Total Assays
2
Approved Drugs
IC50: 52.0, KI: 215.0, EC50: 671.0, KD: 22.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL441738
|
11.0 | EC50 | Approved |
|
|
No preferred name
CHEMBL386081
|
10.7 | EC50 | — |
|
|
No preferred name
CHEMBL3629347
|
10.7 | EC50 | — |
|
|
No preferred name
CHEMBL216295
|
10.7 | EC50 | — |
|
|
No preferred name
CHEMBL386583
|
10.7 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
AFAMELANOTIDE
CHEMBL441738
|
2014 |
Source Header